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Abstract
Background A hallmark symptom of cancer cachexia is the
loss of skeletal muscle. This is at least partially due to a
deregulation of the growth hormone/IGF-1 axis and a
subsequently impaired protein synthesis in skeletal muscle.
Here, we investigated the effect of IGF-1 supplementation
in a rat model of cancer cachexia.
Methods Juvenile rats were inoculated with the Yoshida
AH-130 hepatoma and treated once daily with
0.3 mg kg
−1 day
−1 (low dose) or 3 mg kg
−1 day
−1 (high
dose) IGF-1 or placebo for a period of maximal 16 days.
Body weight and body composition (by NMR) were
assessed at baseline and at the end of the study or day of
death. Locomotor activity and food intake were assessed at
baseline and day 10/11 after tumour inoculation for 24 h.
Results Untreated tumour-bearing rats lost 55.3±2.14 g
body weight, which was reduced by low-dose to −39.6±
11.1 g (p=0.0434) and high-dose IGF-1 to −42.7±8.8 g
(p=0.057). Placebo-treated rats lost 41.4±2.0-g lean mass,
which was attenuated by low-dose IGF-1 (−28.8±8.3 g, p=
0.041) and high-dose IGF-1 (−30.9±7.4, p=0.067). Sponta-
neous activity and food intake were improved by low-dose
IGF-1 only. No effect on fat mass was observed. Low-dose
IGF-1 significantly reduced mortality (HR=0.45, 95%CI=
0.21–0.93, p=0.0315), whilst the high dose did not reach
significance (HR=0.68, 95%CI=0.26–1.74, p=0.42).
Conclusion Low-dose IGF-1 reduced mortality and attenu-
ated loss of body weight as well as muscle mass in the
Yoshida hepatoma rat model. Moreover, an improved
quality of life was observed in these animals. Further
experiments using different doses are necessary.
Keywords Cancer cachexia.Weight loss.Wasting.
Insulin like growth factor-1.Survival.Body composition
1 Introduction
Patients who suffer from cancer cachexia have a poor
quality of life, show increased rates of morbidity and
mortality, as well as a poorer responsiveness to antineo-
plastic therapies [1]. It is estimated that 25% of all cancer
patients die as a result of cachexia, which is a multifactorial
process [2, 3]. In these patients, both proteins and fat are
lost due to wasting. Skeletal muscle accounts for approx-
imately 50% of the body’s protein; hence, it is severely
affected by the condition [4]. At the same time, the major
intrinsic anabolic factor insulin-like growth factor 1 (IGF-
1), which enhances skeletal muscle protein synthesis and
proliferation and differentiation of satellite cells, is reduced
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DOI 10.1007/s13539-011-0029-3cancer cachexia [5]. The effects of IGF-1 on skeletal
muscle are mediated mainly by the PI3K/Akt pathway
leading to the downstream activation of protein synthesis
[6] and inhibition of FOXO-1, which regulates the
expression of the rate-limiting ubiquitin E3-ligases Murf-1
and MAFbx, thereby reducing proteosomal protein degra-
dation [7, 8]. Recombinant IGF-1 has clinically been used
in growth hormone-resistant growth defects in children [9].
However, there have been concerns about side effects that
include arthralgia and hyperplasia of lymph nodes, and an
increased risk for malignancy has been discussed [10].
Interestingly, a study in children with growth impairment
describes the profound effect of IGF-1 leading to increased
BMI and fat mass [11].
Anti-cachectic therapy in patients with cancer cachexia
is so far limited to anabolic steroids, which have not been
very successful and may have serious side effects such
as kidney failure [12]; therefore, treatment alternatives
are urgently needed. Here, the effects of IGF-1 treatment
on body weight, body composition and survival were
assessed in the rat Yoshida hepatoma cancer cachexia
model.
2 Methods
2.1 Animal model
Juvenile Wistar Han rats (weight approx. 200 g) were
injected with 10
8 AH-130 cells into the peritoneum, and the
animals were monitored over a period of maximal 16 days.
Before tumour inoculation, the baseline weight, body
composition, quality of life indicators (spontaneous activity
and food intake) were assessed. Rats were randomized into
placebo (n=37), 0.3 mg kg
−1 day
−1 IGF-1 (n=14) and
3m gk g
−1 day
−1 IGF-1 (n=15). IGF-1 was obtained from
the National Hormone & Peptide Program (Harbor-UCLA
Medical Center, Torrance, USA). IGF-1 or placebo (saline)
was injected subcutaneously once daily. Body composition
and weight were recorded on day 16 or the respective days
of killing, if an animal was killed prematurely due to
reaching ethical endpoints. Locomotor activity and food
intake were determined on day 10/11. At the end of the
study, plasma was collected and the organs were removed
and weighed. Tumour cell number was determined using a
Neubauer chamber.
2.2 Body composition
Body composition (fat and lean body mass) was analysed
with an NMR spectroscopy device EchoMRI-700TM
(Echo Medical Systems, Houston, TX) as described
before [13].
2.3 Quality of life indicators
Animals were housed individually and spontaneous move-
ment recorded by an infrared monitoring system (Supermex,
Muromachi, Tokyo, Japan) over a 24-h period. Also, food
intake was recorded during this period.
2.4 Statistics
Data were analysed using GraphPad PRISM 5.0 (GraphPad
Software, Inc., La Jolla, CA, USA). The results are shown
as mean±SEM. The data were tested for normal distribu-
tion with the Kolmogorov–Smirnov test. Data with normal
distribution were analysed with ANOVA followed by
Student’s t test, whilst data without normal distribution
were analysed by Kruskal–Wallis and Mann–Whitney U
test. Survival was assessed by Cox proportional hazard
analysis. A p value of <0.05 was considered significant.
3 Results
No effect of IGF-1 treatment was observed on tumour
growth; total cell numbers at the end of the study were
2.83±0.42×10
9 and 2.50±0.28×10
9 cells for 0.3 and
3m gk g
−1 day
−1 IGF-1, respectively, whilst untreated rats
had a mean of 2.21±0.23×10
9 cells (p>0.2vs.bothIGF-1
doses). No signs of other malignancies were observed
during necropsy.
3.1 Body weight and body composition
The overall weight loss at the end of the study or day of
death was highest in the placebo group (−55.3±2.14 g) and
was reduced by both low-dose (−39.6±11.1 g, p=0.0434)
and high-dose IGF-1 (−42.7±8.8 g, p=0.057). This is also
seen when the average weight loss per day alive is
calculated (Fig. 1a). As expected, treatment with IGF-1
reduced the wasting of lean body mass, i.e. skeletal muscle.
Placebo-treated rats lost 41.4±2.0 g lean mass, which was
attenuated by low-dose IGF-1 (−28.8±8.3 g, p=0.041) and
high-dose IGF-1 (−30.9±7.4, p=0.067), which is also
observed in loss of lean mass per day alive (Fig. 1b).
Treatment had no effect on overall loss of fat mass
(placebo, −11.5±0.5 g; low-dose IGF-1, −12.4±2 g; high-
dose IGF-1, −11.0±1.3 g, all p>0.1) or the loss of fat mass
per day alive (Fig. 1c).
3.2 Organ weights
As expected, a strong effect on tumour burden was seen on
organ weight. The weight of the liver, spleen, kidney,
brown adipose tissue (BAT), M. extensor digitalis longus
106 J Cachexia Sarcopenia Muscle (2011) 2:105–109(EDL), M. tibialis and M. gastrocnemius (Table 1 and
Fig. 2) was improved by low-dose IGF-1. The high dose
only improved the weight of BAT, EDL, M. tibialis and M.
gastrocnemius (Table 1 and Fig. 2). Heart, lung, white
adipose tissue (WAT, epididymal fat pad) and M. soleus did
not show any changes in weight (Table 1).
3.3 Quality of life
Spontaneous activity and food intake are indicators for the
qualityoflifeofananimal.Baseline24-hspontaneousactivity
and food intake were similar in all groups (all p>0.2,datanot
shown). The activity was reduced by tumour burden in all
groups on day 10/11. Low-dose IGF-1 attenuated the
reduced movement (Fig. 3a), whilst high-dose IGF-1 was
ineffective (p>0.1). This was also observed for food intake
in the high-dose group, whilst low-dose IGF-1 increased
food intake vs. placebo (Fig. 3b).
3.4 Survival
The overall survival was 5% in the placebo group, 21% in
the low-dose and 20% in the high-dose IGF-1 groups
(Fig. 4). The median survival was 12 days in the placebo
group, 14 days in the low-dose and 13 days in the high-
dose IGF-1 groups. Only low-dose IGF-1 significantly
reduced mortality (HR=0.45, 95%CI=0.21–0.93, p=
0.0315), whilst the high dose did not reach significance
(HR=0.68, 95%CI=0.26–1.74, p=0.42).
4 Discussion
We have shown that the tumour growth was not affected by
IGF-1, but the loss of body weight was attenuated, the
avarage loss of lean mass per day alive [g]
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Fig. 1 Average loss of body weight (a), lean body mass (b)a n df a t
mass (c). Data were calculated as change per day alive. IGF-1
reduced loss of body weight and lean mass, but had no effect on fat
mass. **p<0.01
Organ weight (mg) Placebo (n=37) IGF-1 0.3 mg (n=14) IGF-1 3 mg (n=15)
BW baseline (g) 210±2 213±3 211±3
BW end of study (g) 151±3 174±11** 168±10*
heart 505.21±14.00 539.56±31.57 528.51±25.81
lung 885.22±29.57 1,023.54±108.44 925.11±66.35
liver 6,093.39±227.81 7,399.51±440.45* 6,756.66±490.83
spleen 163.64±10.01 266.42±49.29** 217.97±41.39
kidney 698.41±16.58 794.21±24.74** 744.65±25.94
WAT 86.38±26.43 301.20±126.86 146.42±70.90
BAT 78.59±3.14 123.18±14.80*** 109.00±14.39**
Gastrocnemius 713.22±14.07 847.58±51.37** 818.84±52.38*
Soleus 69.73±1.43 76.70±3.49 73.58±3.91
Tibialis 262.49±6.10 325.06±20.48*** 295.74±20.11*
EDL 63.66±1.48 74.04±5.11* 71.98±4.24*
Table 1 Organ and tissue
weights at day 16 (end of study)
or day of death
*p<0.05, **p<0.001, ***p<0.001
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by treatment with IGF-1.
A previous study has shown that IGF-1 levels are lower
in the liver and skeletal muscle of Yoshida AH-130
hepatoma bearing rats, suggesting that impaired IGF-1
signalling is involved in the pathogenesis of muscle wasting
in tumour-bearing rats [5]. A recent publication using
plasmid gene transfer of IGF-1 into M. tibialis of tumour-
bearing mice and rats showed resistance to IGF-1, whilst
the same gene transfer in young and old animals increased
the fibre size [14]. Contrary to these results, a reduction of
weight loss was seen in both Yoshida hepatoma-bearing
groups treated with recombinant IGF-1 in the present study,
where lean body mass loss was reduced. This finding is
supported by the higher weights of the mixed fibre type
muscles M. gastrocnemius and M. tibialis, as well as the
fast-twitch muscle EDL, whilst the weight of the slow-
twitch M soleus was not increased. The contrary results to
the study by Penna et al. [14] are likely due to the
difference in IGF-1 administration and dose. However, our
results also suggest that IGF-1 is not able to fully prevent
skeletal muscle wasting in tumour-bearing rats and that
increasing the dose does not produce better results as the
0.3-mg kg
−1 day
−1 dose was superior to 3-mg kg
−1 day
−1
IGF-1. Together with the lack of effect on the liver,
kidney and spleen weight, this may point to the serious
side effects of high-dose IGF-1, which do not seem to
include increased tumour cell proliferation. Overall, the
incomplete prevention of muscle atrophy may be due to the
increased expression of negative regulators of muscle mass
such as myostatin [15] or the inflammatory cytokines, which
can impair IGF-1 bioavailability and signalling [16]. Fur-
thermore, the half-life of IGF-1 is short [17], which limits its
activity in our study. Ng et al. [18] used a continuous
infusing of IGF-1 in Fischer 344 rats bearing a fibrosarcoma
and showed a preservation of lean mass. In the present study,
treatment had no effect on overall fat mass, supported by the
unchanged weight of the epididymal fat pad, but the weight
of brown adipose tissue was higher in IGF-treated rats,
suggesting an improved thermogenesis [19].
Locomotor activity and food intake are considered
quality of life indicators in animals [20]. Compared with
baseline, a strong decrease in activity and food intake was
seen in all groups 10 days after tumour inoculation, but the
group treated with low-dose IGF-1 had significantly
improved food intake and a higher activity compared with
placebo, suggesting an improved quality of life. High-dose
IGF-1 was ineffective.
The Yoshida hepatoma model has been known to have a
high mortality rate in untreated tumour-bearing rats [21],
which is in accordance with the results of this study. Both
doses of IGF-1 reduced the risk of death (HR=0.45 and
0.68 for the low and high doses, respectively); however,
only the low dose significantly improved outcome com-
pared with placebo.
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Fig. 3 Quality of life: 0.3-mg kg
−1 day
−1 IGF-1 improved spontaneous
activity, as shown by an attenuated reduction compared with baseline
values (a) and total food intake per 24 h (b) on day 10/11 compared
with placebo, whilst 3 mg kg
−1 day
−1 was ineffective.**p<0.01,
***p<0.001
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Fig. 2 Weight of the M. gastrocnemius at the end of the study or
the day of death. IGF-1-treated groups have a higher muscle
weight. **p<0.01
0 2 4 6 8 10 12 14 16
0
20
40
60
80
100
IGF-1 0.3 mg/kg/d (n=14)
IGF-1 3 mg/kg/d (n=15)
Placebo (n=37)
days
Fig. 4 Kaplan–Meier survival curves: 03-mg kg
−1 day
−1 IGF-1
reduced mortality compared with placebo; 3 mg kg
−1 day
−1 is
ineffective
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−1 day
−1 IGF-1 group, reduced mortality
and attenuated loss of body weight, as well as muscle mass,
were seen in the Yoshida hepatoma rat model. Moreover, an
improved quality of life was observed in these animals. The
3-mg kg
−1 day
−1 IGF-1 dose was likely too high and had
weaker effects compared with the lower dose. This may be
due to a decreased sensitivity of target tissue or even
general toxic effects. Therefore, further experiments using
different doses are necessary.
In conclusion, IGF-1 attenuated the development of
cachexia, improved quality of life and survival. The
treatment had no effect on tumour growth. The therapeutic
approach of IGF-1 for tumour-associated cachexia should
be tested in further studies. IGF-1 may be an interesting
candidate for a multidrug approach to treat cancer cachexia.
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